AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual
April 13 2007 - 11:31AM
PR Newswire (US)
QUEBEC CITY, April 13 /PRNewswire-FirstCall/ -- AEterna Zentaris
Inc. (TSX: AEZ; Nasdaq: AEZS), a global, pure play
biopharmaceutical company focused on endocrine therapy and
oncology, today announced that it will present two abstracts
outlining first in vitro data on its PI3K inhibitors as well as in
vivo data on its GHRH antagonist, JMR-132, which both may
potentially provide new therapeutic approaches for the treatment of
cancer. These abstracts will be presented at the American
Association for Cancer Research (AACR) Annual Meeting, to be held
April 14-18 at the Los Angeles Convention Center in Los Angeles,
California. Selected abstracts for poster sessions in the Exhibit
Hall: Monday, April 16, 8:00 a.m. - 12:00 p.m. (PT) - Abstract
#2379 "New Generation of Anilino-Substituted Pyridopyrazine-Urea
Derivatives Show Highly Selective PI3K- Inhibition". Irene Seipelt,
Eckhard Claus, Tilman Schuster, Emmanuel Polymeropoulos, Michael
Teifel, Eckhard Gunther. The abstract reviews, for the first time,
results of a preclinical development program on a new generation of
pyridopyrazine derivatives which clearly indicate that these drug
candidates selectively inhibit PI3K and could be valuable for the
treatment of cancer. Tuesday, April 17, 8:00 a.m. - 12:00 p.m. (PT)
- Abstract #3568 "GHRH-Antagonist in Combination with Docetaxel
Chemotherapy induces regression of MX-1 human experimental breast
cancers". Joerg B. Engel, Andrew V. Schally, Jozseph Varga, Gabor
Halmos, Stefan Buchholz. The abstract reviews results which
demonstrate that GHRH antagonist, JMR-132, inhibits doxorubicin
resistant in MX-1 human breast cancers and induces growth arrest or
total regression when combined with docetaxel chemotherapy.
Consequently, JMR-132 could provide a new therapeutic approach for
the treatment of early and metastatic breast cancer. Copies of
these abstracts are currently available and can be viewed on-line
through the AACR 2007 Meeting website at:
http://www.abstractsonline.com/viewer/?mkey=%7BE3F4019C-0A43-4514-8F66-B86DC90CD935%7D
About AEterna Zentaris Inc. AEterna Zentaris Inc. is a global, pure
play biopharmaceutical company focused on endocrine therapy and
oncology with proven expertise in drug discovery, development and
commercialization. News releases and additional information are
available at http://www.aeternazentaris.com/ Forward-Looking
Statements This press release contains forward-looking statements
made pursuant to the safe harbor provisions of the U.S. Securities
Litigation Reform Act of 1995. Statements that are not historical
facts, including statements preceded by, followed by, or that
include the words "believes", "anticipates", "intends", "plans",
"expects", "estimates", "will," "may", "should", "approximately",
and the negative or other variations of those terms or comparable
terminology, are forward-looking statements. Such statements
reflect management's current views, intentions, strategies and
plans and are based on certain assumptions. Forward-looking
statements involve known and unknown risks and uncertainties, which
could cause the Company's actual results to differ materially from
those in the forward-looking statements. Such risks and
uncertainties include, among others, the ability of AEterna
Zentaris to implement its business strategies, the availability of
funds and resources to pursue R&D projects, the successful and
timely completion of clinical studies, the ability of AEterna
Zentaris to take advantage of business opportunities in the
pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions. Investors
should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to
update these forward-looking statements. DATASOURCE: AETERNA
ZENTARIS INC. CONTACT: Jenene Thomas, Senior Director, Investor
Relations & Corporate Communications, (418) 655-6420, ; Paul
Burroughs, Media Relations, (418) 652-8525 ext. 406,
Copyright